Urbà González | The Cochrane Collaboration (original) (raw)
Papers by Urbà González
Archives of Dermatology, 2007
Question: Does lymphadenectomy performed for microscopic (sentinel node biopsy [SNB]) rather than... more Question: Does lymphadenectomy performed for microscopic (sentinel node biopsy [SNB]) rather than macroscopic (clinically detectable) nodal disease prolong survival in patients with melanoma? Design: Randomized controlled trial. Setting: Multicenter trial performed in hospitals and health centers in the United States, Australia, and Europe. Participants: A total of 1347 patients with primary melanomas of 1.2 to 3.5 mm in thickness were randomized, 20 patients were lost after randomization, and the remaining 1327 were from North America (n=221), Europe (n=386), and Australia (n=720), with 1269 patients finishing the study. Study groups had similar baseline characteristics, and patients were randomly assigned to SNB or observation in a 60:40 ratio. Interventions: Patients with a primary cutaneous melanoma were randomly assigned to the following 2 groups: (1) wide excision and SNB with immediate lymphadenectomy if nodal micrometastases were detected on biopsy (LT-SNB) (n=814) or (2) wide excision and postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred (LT-NM) (n=533). Main Outcome Measures: The primary end point was survival until death from melanoma. Other end points were survival without evidence of nodal recurrence or other metastasis (disease-free survival) and incidence of nodal metastases. Results: Numeric results in the main study groups are summarized in the Table. Five-year melanoma-specific survival rates were similar in the 2 groups. The estimated 5-year disease-free survival rate was higher in the LT-SNB group. Frequency of relapse at any site was greater in the LT-NM group. The incidence of micrometastases in the LT-SNB group was similar to the rate of nodal relapse in the LT-NM group. The incidence of nodal metastases (median follow-up, 59.8 months) was also similar in both groups. An analysis of the subgroups relying on the presence of nodal metastases showed a higher survival rate among patients who underwent lymphadenectomy after a positive SNB result in the LT-SNB group compared with patients who underwent lymphadenectomy in the LT-NM group. Nevertheless, patients who developed nodal metastases after a negative SNB result were excluded from this subgroup analysis. Authors' Conclusions: The interim overall analysis did not reveal a significant difference in melanoma-specific survival between the 2 main study groups. The subgroup analysis among patients with nodal metastases revealed that lymphadenectomy in patients with positive SNB results increases the duration of survival until death from melanoma compared with lymphadenectomy in patients with clinical metastases in the LT-NM group.
The Cochrane database of systematic reviews, Jan 5, 2015
Leishmaniasis is caused by the Leishmania parasite, and transmitted by infected phlebotomine sand... more Leishmaniasis is caused by the Leishmania parasite, and transmitted by infected phlebotomine sandflies. Of the two distinct clinical syndromes, cutaneous leishmaniasis (CL) affects the skin and mucous membranes, and visceral leishmaniasis (VL) affects internal organs. Approaches to prevent transmission include vector control by reducing human contact with infected sandflies, and reservoir control, by reducing the number of infected animals. To assess the effects of vector and reservoir control interventions for cutaneous and for visceral leishmaniasis. We searched the following databases to 13 January 2015: Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS and WHOLIS, Web of Science, and RePORTER. We also searched trials registers for ongoing trials. Randomized controlled trials (RCTs) evaluating the effects of vector and reservoir control interventions in leishmaniasis-endemic regions. Two review authors independently searched for trials and ...
Protocols, 2010
The editorial group responsible for this previously published document have withdrawn it from pub... more The editorial group responsible for this previously published document have withdrawn it from publication.
Evidence-Based Dermatology, 2014
Evidence-Based Dermatology, 2014
Archives of Dermatology, 2011
Objective: To create guidelines for randomized controlled trials (RCTs) investigating interventio... more Objective: To create guidelines for randomized controlled trials (RCTs) investigating interventions used in the management of vitiligo. Participants: Guideline developers included authors (clinicians, patient representatives, and a statistician) of the Cochrane systematic review "Interventions for Vitiligo" plus the coordinator of the vitiligo priority-setting partnership at the Centre of Evidence-Based Dermatology at the University of Nottingham. Evidence: The guidelines are based on the assessment of the quality of design and reporting of RCTs evaluating interventions for vitiligo included in the 2010 update of the Cochrane systematic review "Interventions for Vitiligo." Consensus Process: We reviewed and commented on the sources of bias in existing RCTs on interventions for vitiligo (selection bias, blinding assessment, attrition bias, characteristics of participants, interventions, and outcomes) based on the findings of the Cochrane review, and we used open discussion on guideline drafts focusing on the study question (participants, interventions, and outcomes), study design (research methods), and reporting. Conclusions: Much opportunity exists for improving the design and reporting of vitiligo clinical trials. The proposed guidelines will help overcome methodologic challenges faced when conducting RCTs to answer treatment questions.
Archives of Dermatology, 2002
... Urbà González, MD,PhD. Arch Dermatol. 2002;138:1604-1606. Commentary on: Fluconazole for the ... more ... Urbà González, MD,PhD. Arch Dermatol. 2002;138:1604-1606. Commentary on: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH N Engl J Med. 2002;346:891-895. ...
Medicina cutánea ibero-latino-americana
ABSTRACT
Medicina Clínica
The arteriovenous fistula is the vascular access of choice for hemodialysis treatment in patients... more The arteriovenous fistula is the vascular access of choice for hemodialysis treatment in patients with chronic renal failure. Clinical occurrence of local circulatory troubles caused by the fistula in addition to arterial robbery or venous hypertension are infrequent but may provoke serious consequences. Two patients with arteriovenous fistula with cutaneous trophic disorders secondary to the venous hypertension syndrome (case 1) and to the arterial robbery syndrome (case 2) are present. Prevalence, pathogenic factors, physiopathology, clinical aspects, and diagnosis and treatment of both syndromes are reviewed. Finally, the difficulty and morbidity of the creation of an efficient arteriovenous fistula in the diabetic patient is underlined.
Reviews, 1996
This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration a... more This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com ... Vaccines for preventing cutaneous leishmaniasis (Protocol) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ... Vaccines for preventing cutaneous leishmaniasis (Protocol) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ... [Intervention Protocol] Vaccines for preventing cutaneous leishmaniasis
Cochrane database of systematic reviews (Online), 2010
Around one per cent of the world's population has vitiligo, a disease which causes white pat... more Around one per cent of the world's population has vitiligo, a disease which causes white patches on the skin. There are a variety of treatments available, most of which are unsatisfactory.
Archives of Dermatology, 2008
These principles, developed jointly by editorial and publishing staff, are applied by the America... more These principles, developed jointly by editorial and publishing staff, are applied by the American Medical Association (AMA) to ensure adherence to the highest ethical standards of advertising and to determine the eligibility of products and services for advertising in the AMA's print and digital publications.
Archives of Dermatology, 2007
Question: Does lymphadenectomy performed for microscopic (sentinel node biopsy [SNB]) rather than... more Question: Does lymphadenectomy performed for microscopic (sentinel node biopsy [SNB]) rather than macroscopic (clinically detectable) nodal disease prolong survival in patients with melanoma? Design: Randomized controlled trial. Setting: Multicenter trial performed in hospitals and health centers in the United States, Australia, and Europe. Participants: A total of 1347 patients with primary melanomas of 1.2 to 3.5 mm in thickness were randomized, 20 patients were lost after randomization, and the remaining 1327 were from North America (n=221), Europe (n=386), and Australia (n=720), with 1269 patients finishing the study. Study groups had similar baseline characteristics, and patients were randomly assigned to SNB or observation in a 60:40 ratio. Interventions: Patients with a primary cutaneous melanoma were randomly assigned to the following 2 groups: (1) wide excision and SNB with immediate lymphadenectomy if nodal micrometastases were detected on biopsy (LT-SNB) (n=814) or (2) wide excision and postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred (LT-NM) (n=533). Main Outcome Measures: The primary end point was survival until death from melanoma. Other end points were survival without evidence of nodal recurrence or other metastasis (disease-free survival) and incidence of nodal metastases. Results: Numeric results in the main study groups are summarized in the Table. Five-year melanoma-specific survival rates were similar in the 2 groups. The estimated 5-year disease-free survival rate was higher in the LT-SNB group. Frequency of relapse at any site was greater in the LT-NM group. The incidence of micrometastases in the LT-SNB group was similar to the rate of nodal relapse in the LT-NM group. The incidence of nodal metastases (median follow-up, 59.8 months) was also similar in both groups. An analysis of the subgroups relying on the presence of nodal metastases showed a higher survival rate among patients who underwent lymphadenectomy after a positive SNB result in the LT-SNB group compared with patients who underwent lymphadenectomy in the LT-NM group. Nevertheless, patients who developed nodal metastases after a negative SNB result were excluded from this subgroup analysis. Authors' Conclusions: The interim overall analysis did not reveal a significant difference in melanoma-specific survival between the 2 main study groups. The subgroup analysis among patients with nodal metastases revealed that lymphadenectomy in patients with positive SNB results increases the duration of survival until death from melanoma compared with lymphadenectomy in patients with clinical metastases in the LT-NM group.
The Cochrane database of systematic reviews, Jan 5, 2015
Leishmaniasis is caused by the Leishmania parasite, and transmitted by infected phlebotomine sand... more Leishmaniasis is caused by the Leishmania parasite, and transmitted by infected phlebotomine sandflies. Of the two distinct clinical syndromes, cutaneous leishmaniasis (CL) affects the skin and mucous membranes, and visceral leishmaniasis (VL) affects internal organs. Approaches to prevent transmission include vector control by reducing human contact with infected sandflies, and reservoir control, by reducing the number of infected animals. To assess the effects of vector and reservoir control interventions for cutaneous and for visceral leishmaniasis. We searched the following databases to 13 January 2015: Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS and WHOLIS, Web of Science, and RePORTER. We also searched trials registers for ongoing trials. Randomized controlled trials (RCTs) evaluating the effects of vector and reservoir control interventions in leishmaniasis-endemic regions. Two review authors independently searched for trials and ...
Protocols, 2010
The editorial group responsible for this previously published document have withdrawn it from pub... more The editorial group responsible for this previously published document have withdrawn it from publication.
Evidence-Based Dermatology, 2014
Evidence-Based Dermatology, 2014
Archives of Dermatology, 2011
Objective: To create guidelines for randomized controlled trials (RCTs) investigating interventio... more Objective: To create guidelines for randomized controlled trials (RCTs) investigating interventions used in the management of vitiligo. Participants: Guideline developers included authors (clinicians, patient representatives, and a statistician) of the Cochrane systematic review "Interventions for Vitiligo" plus the coordinator of the vitiligo priority-setting partnership at the Centre of Evidence-Based Dermatology at the University of Nottingham. Evidence: The guidelines are based on the assessment of the quality of design and reporting of RCTs evaluating interventions for vitiligo included in the 2010 update of the Cochrane systematic review "Interventions for Vitiligo." Consensus Process: We reviewed and commented on the sources of bias in existing RCTs on interventions for vitiligo (selection bias, blinding assessment, attrition bias, characteristics of participants, interventions, and outcomes) based on the findings of the Cochrane review, and we used open discussion on guideline drafts focusing on the study question (participants, interventions, and outcomes), study design (research methods), and reporting. Conclusions: Much opportunity exists for improving the design and reporting of vitiligo clinical trials. The proposed guidelines will help overcome methodologic challenges faced when conducting RCTs to answer treatment questions.
Archives of Dermatology, 2002
... Urbà González, MD,PhD. Arch Dermatol. 2002;138:1604-1606. Commentary on: Fluconazole for the ... more ... Urbà González, MD,PhD. Arch Dermatol. 2002;138:1604-1606. Commentary on: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH N Engl J Med. 2002;346:891-895. ...
Medicina cutánea ibero-latino-americana
ABSTRACT
Medicina Clínica
The arteriovenous fistula is the vascular access of choice for hemodialysis treatment in patients... more The arteriovenous fistula is the vascular access of choice for hemodialysis treatment in patients with chronic renal failure. Clinical occurrence of local circulatory troubles caused by the fistula in addition to arterial robbery or venous hypertension are infrequent but may provoke serious consequences. Two patients with arteriovenous fistula with cutaneous trophic disorders secondary to the venous hypertension syndrome (case 1) and to the arterial robbery syndrome (case 2) are present. Prevalence, pathogenic factors, physiopathology, clinical aspects, and diagnosis and treatment of both syndromes are reviewed. Finally, the difficulty and morbidity of the creation of an efficient arteriovenous fistula in the diabetic patient is underlined.
Reviews, 1996
This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration a... more This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com ... Vaccines for preventing cutaneous leishmaniasis (Protocol) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ... Vaccines for preventing cutaneous leishmaniasis (Protocol) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ... [Intervention Protocol] Vaccines for preventing cutaneous leishmaniasis
Cochrane database of systematic reviews (Online), 2010
Around one per cent of the world's population has vitiligo, a disease which causes white pat... more Around one per cent of the world's population has vitiligo, a disease which causes white patches on the skin. There are a variety of treatments available, most of which are unsatisfactory.
Archives of Dermatology, 2008
These principles, developed jointly by editorial and publishing staff, are applied by the America... more These principles, developed jointly by editorial and publishing staff, are applied by the American Medical Association (AMA) to ensure adherence to the highest ethical standards of advertising and to determine the eligibility of products and services for advertising in the AMA's print and digital publications.